Vista Oil & Gas, S.A.B. de C.V. Stock News

Vista Oil & Gas, S.A.B. de C.V. Sponsored ADR (VIST) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?

Vista Energy, S.A.B. de C.V. (NYSE:VIST ) Q1 2022 Earnings Conference Call April 28, 2022 9:00 AM ET Company Participants Alejandro Cherñacov - Strategic Planning & Investor Relations Officer Miguel

While higher commodity prices are likely to have boosted Vista Oil & Gas' (VIST) profit levels in the first quarter, escalation in lifting costs might have played spoilsport.

Vista Oil & Gas, S.A.B. de C.V. Sponsored ADR (VIST) saw its shares surge in the last session with trading volume being higher than average.

With many investors looking for oil and gas plays to profit from recent increases in the oil price, Vista Oil & Gas will likely receive more and more attention.

Las Vegas, USA, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Global Dengue Fever Pipeline Insights | Clinical Trials Evaluation Research Report 2022 by DelveInsight Dengue Fever Pipeline constitutes 20+ key companies continuously working towards developing 20+ Dengue Fever treatment therapies, analyzes DelveInsight DelveInsight''s ‘ Dengue Fever Pipeline Insight 2022'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Dengue Fever pipeline domain. Some of the essential takeaways from the Dengue Fever Pipeline report: DelveInsight''s Dengue Fever Pipeline analysis depicts a robust space with 20+ active players proactively working to develop 20+ pipeline treatment therapies. Some of the key Dengue companies working to develop potential drug candidates to improve the Dengue Fever treatment scenario include Kino Pharma, Emergex Vaccines, Abivax, Plex Pharmaceuticals, Takeda, Merck Sharp & Dohme, Immunoforge, Chugai Pharmaceutical Co., Ltd, Codagenix, Biotron Ltd, GlaxoSmithKline, Ennaid therapeutics, AbViro LLC, Medigen Vaccine Biologics Corp., Atea Pharmaceuticals, Visterra, Janssen Research & Development, Globavir Biosciences, Serum Institute of India, BioNet Asia, and many others.

CCS, COWN, and VIST made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 24, 2022

Vista Oil & Gas, S.A.B. de C.V (VIST) CEO Miguel Galuccio on Q4 2021 Results - Earnings Call Transcript

Vista Oil & Gas, S.A.B. de C.V. Sponsored ADR (VIST) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Parametric Portfolio Associates LLC reduced its holdings in shares of Vista Oil & Gas, S.A.B. de C.V. (NYSE:VIST) by 5.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 149,637 shares of the companys stock after selling 8,616 shares during the quarter. Parametric []

Goldman Sachs Group Inc. lessened its stake in shares of Vista Oil & Gas, S.A.B. de C.V. (NYSE:VIST) by 36.5% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 36,162 shares of the companys stock after selling 20,825 shares during the period. Goldman Sachs Group [] The post Goldman Sachs Group Inc. Has $148,000 Position in Vista Oil & Gas, S.A.B. de C.V. (NYSE:VIST) appeared first on ETF Daily News .